Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Charles Chuah"'
Autor:
Wei Xiang, Colin Sng, Yi-Hui Lam, Ze-Hui Kok, Yeh-Ching Linn, Soek-Ying Neo, Yin-Yin Siew, Deepika Singh, Hwee-Ling Koh, Charles Chuah
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7958 (2024)
While BCR::ABL1 tyrosine kinase inhibitors have transformed the treatment paradigm for chronic myeloid leukemia (CML), disease progression and treatment resistance due to BCR::ABL1-dependent and BCR::ABL1-independent mechanisms remain a therapeutic c
Externí odkaz:
https://doaj.org/article/b3e1cebcf53244eab485a851cc5c3a83
Autor:
Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James Mccloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley
Publikováno v:
HemaSphere, Vol 7, p e85501cf (2023)
Externí odkaz:
https://doaj.org/article/f0b8d7a160ec4ce1b84d936813ace846
Autor:
Martin C. Müller, Jorge Cortes, Charles Chuah, Daniel Deangelo, Michael Deininger, François Guilhot, Timothy Hughes, Franck Emmanuel Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Neil P. Shah, Moshe Talpaz, Vickie Lu, Thihan Padukkavidana, Hagop Kantarjian
Publikováno v:
HemaSphere, Vol 7, p e88427a9 (2023)
Externí odkaz:
https://doaj.org/article/eb3dd58a194242debe7a5d6162af5c8c
Publikováno v:
Genetics in Medicine Open, Vol 1, Iss 1, Pp 100219- (2023)
Externí odkaz:
https://doaj.org/article/d59f9e4061ea474f899329fe724a8e8d
Publikováno v:
Translational Oncology, Vol 12, Iss 9, Pp 1221-1228 (2019)
Despite the efficacy of BCR-ABL tyrosine kinase inhibitors (TKIs) in chronic phase-chronic myeloid leukemia, the management of blast phase-chronic myeloid leukemia (BP-CML) remains a challenge. Therefore, there is an urgent need to identify alternati
Externí odkaz:
https://doaj.org/article/0ecce51b09e84c25984416c3d971441d
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 5, p 2863 (2022)
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the acc
Externí odkaz:
https://doaj.org/article/2e5920a90ff5424c863057e93f057fd0
Autor:
Simon T. Durrant, Arnon Nagler, Paola Guglielmelli, David Lavie, Philipp le Coutre, Heinz Gisslinger, Charles Chuah, Margherita Maffioli, Savita Bharathy, Tuochuan Dong, Monika Wroclawska, Joaquin Martinez Lopez
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Externí odkaz:
https://doaj.org/article/23007674ea0f424e85116d58d505317f
Autor:
King Pan Ng, Aditi Manjeri, Lin Ming Lee, Zhu En Chan, Chin Yee Tan, Qiancheng Darren Tan, A'Qilah Majeed, Kian Leong Lee, Charles Chuah, Toshio Suda, S Tiong Ong
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205254 (2018)
Cancer cells, including in chronic myeloid leukemia (CML), depend on the hypoxic response to persist in hosts and evade therapy. Accordingly, there is significant interest in drugging cancer-specific hypoxic responses. However, a major challenge in l
Externí odkaz:
https://doaj.org/article/05aac69187304e089d4f5ac477267de7
Autor:
Charles Chuah, Junia V Melo
Publikováno v:
OncoTargets and Therapy, Vol 2009, Iss default, Pp 83-94 (2009)
Charles Chuah1, Junia V Melo21Singapore General Hospital and Duke-NUS Graduate Medical School, Singapore; 2Institute of Medical and Veterinary Science, South Australia, AustraliaAbstract: The efficacy of imatinib in chronic myeloid leukemia has been
Externí odkaz:
https://doaj.org/article/bf0154c034954d628a527cd8708ceb86
Autor:
Franck E. Nicolini, Amr R. Ibrahim, Simona Soverini, Giovanni Martinelli, Martin C. Müller, Andreas Hochhaus, Inge H. Dufva, Dong-Wook Kim, Jorge Cortes, Michael J. Mauro, Charles Chuah, Hélène Labussière, Stéphane Morisset, Catherine Roche-Lestienne, Eric Lippert, Sandrine Hayette, Senaka Peter, Wei Zhou, Véronique Maguer-Satta, Mauricette Michallet, John Goldman, Jane F. Apperley, François-Xavier Mahon, David Marin, Gabriel Etienne
Publikováno v:
Haematologica, Vol 98, Iss 10 (2013)
The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed. Us
Externí odkaz:
https://doaj.org/article/63895084e4e04e2a8f5eeb38e81c752e